Working to make the promise of precision medicine a reality
Mike A. Sherman
Chief Executive Officer/President
Mike Sherman joined Endocyte in 2006 and was recently named Chief Executive Officer and President. Mr. Sherman previously served as chief operating officer and chief financial officer. Prior to joining Endocyte, Mr. Sherman served in various executive roles, most recently as vice president of finance and strategic planning of Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation, a medical device company. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth. Mr. Sherman serves as Vice Chairman on the Board of Trustees for the Indianapolis Children’s Museum. He also served on the Board of Directors at Mead Johnson Nutrition.
Michael T. Andriole
Chief Financial Officer
Michael Andriole joined the company in February 2017 as chief financial officer. Prior to joining Endocyte, Mr. Andriole served as vice president, corporate business development at Eli Lilly and Company with responsibility for international transactions, including in/out licensing, JV formation and M&A. Mr. Andriole has more than 20 years of experience in a range of financial, strategic and corporate development roles, as well as broad finance and strategic transaction experience across multiple therapeutic areas, including strategic transactions in oncology, immunology and neuroscience. Mr. Andriole graduated cum laude from Xavier University’s Williams College of Business. He holds his MBA from Indiana University’s Kelly School of Business.
Alison Armour, M.B., Ch.B., B.Sc., M.Sc., M.D., MRCP., FRCR
Chief Medical Officer
Dr. Alison Armour joined the company as chief medical officer in August 2015. Prior to joining Endocyte, Dr. Armour served as vice president of oncology at Novartis and GSK, where she led the global strategic TYKERB development team in breast cancer and was accountable for a large matrix team composed of clinical, medical, regulatory, statistics, medical affairs, science and commercial colleagues based in multiple sites in the US, UK and Japan. Prior to Novartis and GSK, she was the global medical science director at AstraZeneca and led the development and approval of IRESSA, the first EGFR RTKi registered in first line EGFR mutation positive non-small cell lung cancer. Before joining industry, Dr. Armour established herself as a thought leader in medical and radiation oncology. Dr. Armour holds her B.Sc. in biochemistry, M.B., Ch.B. MSc, and Doctorate of Medicine from the University of Glasgow, MRCP at the Member of the Royal College of Physicians Glasgow, and her FRCR at the Royal College of Radiologists London, UK.
Vice President, Clinical Operations
Caryn Barnett joined Endocyte in January 2018 and was promoted to vice president of clinical operations in November 2018. Ms. Barnett has over 23 years of drug development experience. Prior to joining Endocyte, she worked at Eli Lily and Company in numerous roles in research and development, primarily in clinical. Ms. Barnett has worked across pre-clinical to post approval settings with experience in operations, project management and quality. She holds a BSN in nursing from West Virginia University and an MSN in nursing from Indiana University.
Vice President, Business Development & Marketing
Matthew Call joined Endocyte in 2003 as director of business development and has served as vice president of business development since 2012. He is responsible for all strategic partnering and licensing transactions. Mr. Call has led numerous successful partnering processes, including Endocyte’s transformational billion-dollar partnership with Merck for vintafolide. Prior to joining Endocyte, Mr. Call spent several years working in business development in information technology, where he structured and managed strategic relationships with firms such as Hewlett-Packard, General Electric, First Data Corporation, and Disney. He holds a BA from Brigham Young University and an MBA from Purdue University.
Erik C. Chelius, PhD
Vice President, CMC
Dr. Erik Chelius has served as our Vice President of CMC since January 2018. He previously served as our senior director of CMC and as a senior research scientist. Prior to joining Endocyte, Dr. Chelius worked in the development and manufacturing departments of Eli Lilly & Co. He also has contract manufacturing experience gained while employed at Evonik. He holds a BS in chemistry from Marquette University and an MS and PhD in chemistry from Northwestern University.
Katherine K. Dean
Vice President, Human Resources
Katherine Dean joined Endocyte in 2013 and serves as the vice president of human resources. Prior to joining Endocyte, Ms. Dean served in various entrepreneurial and executive roles such as vice president of human resources and administrative services for Hyundai Motor America, the North American headquarters for Hyundai Automotive Group. She holds a BA in history from the University of California, Los Angeles and an MBA from California State University. Ms. Dean also serves on the Board of Directors at West Lafayette Schools Education Foundation and Wabash Center.
Christopher Jordan, MSHS, RAC
Vice President, Regulatory Affairs
Christopher Jordan joined Endocyte in 2013 and was recently named Vice President of Regulatory Affairs. Prior to joining Endocyte, Mr. Jordan spent more than 25 years at Eli Lilly in a variety of drug development roles covering pre-clinical to post approval settings, including regulatory team leader for drug development and drug/device combination products. He holds his BS in chemistry from Purdue University and an MSHS in regulatory affairs from George Washington University.
Christopher P. Leamon, PhD
Vice President, Research & Development
Dr. Christopher Leamon joined Endocyte in 1999 as our director of biology and biochemistry. He currently serves as our vice president of research and development. Prior to joining Endocyte, Dr. Leamon was employed in the pharmaceutical industry where he conducted discovery research in the field of peptide, oligonucleotide, liposome, and DNA drug delivery for GlaxoSmithKline, a healthcare company, and Ionis Pharmaceuticals, a biomedical pharmaceutical company. He holds a BS in chemistry from Baldwin Wallace University and a PhD in biochemistry from Purdue University.
Philip S. Low, PhD
Chief Science Officer
Dr. Philip Low is one of our founders and has served as our chief science officer since 1998 and as a member of our Board of Directors since 1995. Dr. Low has served on the faculty at Purdue University since August 1976, where he is currently the Ralph C. Corley Distinguished Professor of Chemistry. He holds a BS in chemistry from Brigham Young University and a PhD in biochemistry from the University of California, San Diego.
David R. McAvoy, MSES, JD
General Counsel and Chief Compliance Officer
David McAvoy joined Endocyte in January 2018 and serves as General Counsel and Chief Compliance Officer. Before this, Mr. McAvoy was at Eli Lilly and Company, most recently as General Counsel of Lilly Emerging Markets – at the time, a $3 billion company division – and then in an executive management role running strategic alliances for the food animal production group at Lilly’s former Elanco Animal Health subsidiary. At Lilly, Mr. McAvoy was lead counsel for several iconic medicines, including Prozac® for depression, Gemzar® for pancreatic/lung cancers, and ReoPro®, one of the first interventional cardiology agents. He partnered with FDA to create important policy precedents in orphan drug, direct-to-consumer advertising of pharmaceuticals, and clinical trial transparency. Mr. McAvoy earned a JD and MS in Environmental Science with highest honors from Indiana University, and a BA in political science from the University of Notre Dame. He serves on the Board of Directors for The Villages of Indiana, Inc., championing families for abandoned and abused children.
Richard Messmann, MD, MHS, MSc
Vice President, Medical Affairs
Dr. Messmann joined Endocyte as senior director of medical affairs in early 2018 and now serves as vice president of medical affairs. Dr. Messmann is a medical oncologist with over 20 years of experience in conducting phase I-III clinical studies within government, academia and industry. After completing a medical oncology fellowship at the National Cancer Institute and obtaining an MHS in health science from Duke University, he served as deputy associate director of the NCI’s developmental therapeutics program (DTP) and as an attending physician for NCI clinical trials, specializing in the transition of experimental therapeutics from the late-preclinical stage into first-in-human phase I and phase II studies. Dr. Messmann has held leadership positions at Eli Lilly, Great Lakes Cancer Institute, ProNAi Therapeutics and Apexian Pharmaceuticals.
Beth A. Taylor, CPA
Vice President, Finance
Beth Taylor joined Endocyte as corporate controller in January 2011 and now serves as vice president of finance and chief accounting officer. She is responsible for financial planning, reporting, and control compliance. Ms. Taylor started her career with Deloitte and then served in various financial roles with Rolls-Royce and vice president and controller for Republic Airways. She has also served as corporate controller for companies owned by private equity firms to assist with building strong financial and control processes. She holds a BS in accounting from Kelly School of Business from Indiana University and holds a CPA license from the state of Indiana. She is a member of Financial Executives International (FEI) and holds a board position for the Indianapolis Chapter.
Iontcho Vlahov, PhD
Vice President, Discovery Chemistry
Dr. Iontcho Vlahov joined Endocyte in 1999 and serves as the vice president of discovery chemistry. . Before joining Endocyte, he was the head of discovery chemistry at Ivax Corp in Miami, Florida. Prior to that, he held various positions, including visiting scientist at Hercules, Inc.; senior research scientist at the University of Konstanz, Germany; research scientist at the Institute of Organic Chemistry, Bulgarian Academy of Sciences; and research associate at the University of Iowa. Dr. Vlahov is an Alexander von Humboldt Fellow and has published more than 55 scientific articles and 15 patents. He received his PhD in synthetic organic and structural chemistry from Ruhr University, Bochum, Germany.